At the time of writing, Arcus Biosciences Inc [RCUS] stock is trading at $13.41, up 1.59%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RCUS shares have gain 2.44% over the last week, with a monthly amount drifted -11.37%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Arcus Biosciences Inc [NYSE: RCUS] stock has seen the most recent analyst activity on October 21, 2024, when H.C. Wainwright initiated its Neutral rating and assigned the stock a price target of $20. Previously, Wells Fargo started tracking the stock with Overweight rating on October 08, 2024, and set its price target to $29. On November 18, 2022, BofA Securities initiated with a Neutral rating and assigned a price target of $33 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $40 on October 11, 2022. Berenberg started tracking with a Buy rating for this stock on November 24, 2020, and assigned it a price target of $50. In a note dated November 23, 2020, Evercore ISI initiated an Outperform rating.
For the past year, the stock price of Arcus Biosciences Inc fluctuated between $12.53 and $20.31. Currently, Wall Street analysts expect the stock to reach $30.6 within the next 12 months. Arcus Biosciences Inc [NYSE: RCUS] shares were valued at $13.41 at the most recent close of the market. An investor can expect a potential return of 128.19% based on the average RCUS price forecast.
Analyzing the RCUS fundamentals
According to Arcus Biosciences Inc [NYSE:RCUS], the company’s sales were 263.00M for trailing twelve months, which represents an 50.00% jump. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -1.21%, Pretax Profit Margin comes in at -1.02%, and Net Profit Margin reading is -1.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.46 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.04 points at the first support level, and at 12.67 for the second support level. However, for the 1st resistance point, the stock is sitting at 13.76, and for the 2nd resistance point, it is at 14.10.
Ratios To Look Out For
It is important to note that Arcus Biosciences Inc [NYSE:RCUS] has a current ratio of 5.23. Also, the Quick Ratio is 5.23, while the Cash Ratio stands at 0.93. Considering the valuation of this stock, the price to sales ratio is 4.67, the price to book ratio is 2.17.
Transactions by insiders
Recent insider trading involved Goeltz II Robert C., Chief Financial Officer, that happened on Dec 31 ’24 when 3594.0 shares were sold. Officer, Goeltz II Robert C. completed a deal on Dec 31 ’24 to buy 3594.0 shares. Meanwhile, Chief Accounting Officer Azoy Alexander sold 201.0 shares on Dec 02 ’24.
